Baxter International (NYSE:BAX) will be announcing its earnings results before the market opens on Thursday, April 26th. Analysts expect the company to announce earnings of $0.64 per share for the quarter. Baxter International has set its Q1 guidance at $0.60-0.62 EPS and its FY18 guidance at $2.72-2.80 EPS.
Baxter International (NYSE:BAX) last posted its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.05. Baxter International had a return on equity of 15.11% and a net margin of 6.79%. The company had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.77 billion. During the same period in the prior year, the business earned $0.57 earnings per share. Baxter International’s revenue for the quarter was up 4.9% compared to the same quarter last year. On average, analysts expect Baxter International to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
BAX opened at $66.15 on Wednesday. Baxter International has a 1-year low of $53.04 and a 1-year high of $72.58. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.57 and a quick ratio of 2.05. The company has a market capitalization of $36,216.31, a PE ratio of 26.67, a price-to-earnings-growth ratio of 1.83 and a beta of 0.80.
Baxter International announced that its board has authorized a stock repurchase plan on Tuesday, February 20th that allows the company to repurchase $1.50 billion in shares. This repurchase authorization allows the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company’s management believes its shares are undervalued.
The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 2nd. Stockholders of record on Friday, March 2nd were given a $0.16 dividend. The ex-dividend date was Thursday, March 1st. This represents a $0.64 annualized dividend and a dividend yield of 0.97%. Baxter International’s dividend payout ratio is 25.81%.
Several equities research analysts have recently weighed in on BAX shares. Zacks Investment Research cut Baxter International from a “buy” rating to a “hold” rating in a research report on Tuesday, December 26th. Bank of America raised Baxter International from a “neutral” rating to a “buy” rating in a research report on Tuesday, January 2nd. Evercore ISI assumed coverage on Baxter International in a research report on Wednesday, January 3rd. They issued an “outperform” rating and a $71.00 target price for the company. Royal Bank of Canada reaffirmed a “hold” rating and issued a $72.00 target price on shares of Baxter International in a research report on Friday, February 2nd. Finally, ValuEngine cut Baxter International from a “buy” rating to a “hold” rating in a research report on Wednesday, March 7th. Six research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. Baxter International currently has a consensus rating of “Buy” and a consensus target price of $71.13.
In other Baxter International news, Director James R. Gavin III sold 18,750 shares of Baxter International stock in a transaction on Wednesday, March 28th. The stock was sold at an average price of $64.56, for a total transaction of $1,210,500.00. Following the completion of the transaction, the director now directly owns 36,398 shares of the company’s stock, valued at $2,349,854.88. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Peter S. Hellman sold 3,760 shares of Baxter International stock in a transaction on Monday, April 2nd. The shares were sold at an average price of $64.74, for a total value of $243,422.40. Following the transaction, the director now directly owns 25,522 shares of the company’s stock, valued at $1,652,294.28. The disclosure for this sale can be found here. Over the last three months, insiders have sold 27,500 shares of company stock valued at $1,783,512. Company insiders own 0.07% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was published by Macon Daily and is the sole property of of Macon Daily. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://macondaily.com/2018/04/25/baxter-international-bax-set-to-announce-earnings-on-thursday.html.
About Baxter International
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.